Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Background Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aimed to evaluate the use of ipilimumab and anti-PD-...

Full description

Bibliographic Details
Main Authors: Vikki Tang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Bryan Cho Wing Li, Ka Wing Ma, Wong Hoi She, Chung Mau Lo
Format: Article
Language:English
Published: BMJ Publishing Group 2021-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/2/e001945.full

Internet

https://jitc.bmj.com/content/9/2/e001945.full

Similar Items